Company intelligence / Profile preview

Regenetech

Ownership: Private
Development stage: Commercial

Overview

Regenetech developed proprietary technology—originally discovered through NASA space experiments—for expanding adult stem cells in three dimensions. The company licensed this technology globally and entered into partnerships for developing therapies targeting major unmet needs such as neurodegenerative disorders and cardiovascular conditions. It was acquired by Healthcare of Today in 2008.

Therapeutic areas: OncologyImmunologyHematologyCardiovascularNeurology
Modalities: Cell therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

OXAID

Development

Indications: Chronic wounds, Diabetic wounds

Partnerships

Biogenea–Cellgenea (Greece) – Licensing agreement for development/adult stem cell therapies targeting multiple indications including Parkinson's disease and spinal cord injury

Beyond the preview

Go deeper on Regenetech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regenetech.

Explore the full profile